Skip to content
Menu

Quoin Pharmaceuticals, Ltd. QNRX

Full chart Compare
Set alert

Price alert · QNRX

All alert types
3.70 USD 0.00 (+0.00%)

Regular-session close

3.65 -0.05 -1.35%

Pre-market · Nov 16, 8:33 AM ET

3.55 Day range 3.99
3.25 52-week range 23.50
YTD
-74.36%
1 year
-72.43%
Market cap
17.78M
EPS (ttm)
0.44
Shares out
5.05M
P/E ratio
8.41
Forward P/E
-0.43
YTD return
-74.36%
1-year return
-72.43%
50-day average
0.69104
200-day average
0.6863
Volume
16.03K
Avg volume
542.37K
Open
3.99
Previous close
3.70
Day's range
3.55 – 3.99
52-week range
3.25 – 23.50
Beta
1.89
Analysts
Strong Buy
Price target
4.50 (+21.6%)

5D -0.05 (-1.31%)

3.603.804ThuFriMonTueWed3.76

Key statistics

Enterprise value
-6.59M
Price / book
0.09
Free cash flow
-5.05M
Total cash
12.57M
Total debt
3.22M
Return on equity
-100.03%
Short % of float
0.48%

Fundamental scorecard

6 of 25 checks passed on QNRX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth No data
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
QNRX Revenue — quarterly 0
QNRX Net income — quarterly -4.87M

Earnings

QNRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.44-0.47-0.03-6.82%
Aug 8, 2024Jun 1, 2024-0.75-0.39+0.36+48.00%
May 9, 2024Mar 1, 20240.00-1.11——
Mar 13, 2024Dec 1, 2023-2.37-2.08+0.29+12.24%
Nov 8, 2023Sep 1, 2023-2.40-1.95+0.45+18.75%
Aug 2, 2023Jun 1, 20230.00-2.13——

Upgrades / downgrades

QNRX analyst upgrades and downgrades
DateFirmActionFromTo
Mar 15, 2024Maxim GroupmainBuyBuy

About Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on QNRX — it syncs with the Stock Master app.

Insider holders

QNRX insider holders
InsiderRelationLatest transactionDateShares held
CARTER DENISE PChief Operating OfficerPurchaseSep 3, 202447,092
DUNN GORDONChief Financial OfficerPurchaseSep 9, 202428,856
MYERS MICHAELChief Executive OfficerPurchaseSep 3, 202447,252

Institution ownership

QNRX institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC0.77%38,69120.20KSep 29, 2024
Two Sigma Securities, LLC0.63%31,85416.63KSep 29, 2024
Raymond James Financial Services Advisors, Inc.0.50%25,11913.11KSep 29, 2024
Virtu Financial LLC0.50%25,16513.14KSep 29, 2024
UBS Group AG0.45%22,82111.91KSep 29, 2024
Rhumbline Advisers0.41%20,78610.85KSep 29, 2024

Fund ownership

QNRX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.00%9549Apr 29, 2024